Efficacy of infliximab treatment in patients with severe Hidradenitis Suppurativa

Elkjær, Margarita; Dinesen, Lars; Benazzato, L.; Jess, Tine; Riis, Lene; Caspersen, Sarah; Rodriguez, San Pío J; Løgager, Vibeke; Munkholm, Pia

doi:10.1097/00054725-200705001-00063

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 11 papers, a total of 22 patients receiving maintenance treatment were described (20, 26, 28, 29, [30][31][32][33][36][37][38]. In the majority of case reports the maintenance treatment was given throughout the time for follow-up.…”

Section: Infliximab (Refs 19-38mentioning

confidence: 99%

“…In the majority of case reports the maintenance treatment was given throughout the time for follow-up. In 2 reports (4 patients) the treatment was stopped when improvement was obtained and continued effect was reported up to years (33,36). There was a great variation in the overall duration of treatment, in one case up to 2 years (20) and the intervals between the infusions were between 4 and 8 weeks.…”

Section: Infliximab (Refs 19-38mentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors

Haslund¹,

Lee²,

Jemec³

2009

Acta Derm Venerol

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a common inflammatory skin disease. Medical treatment is often disappointing and in severe disease surgery remains the therapy of choice. Extensive surgery may be effective but also mutilating. Patients experience a significant reduction in quality of life and the need for new treatment modalities are urgent. In recent years patients with HS have been treated off-label with tumour necrosis factor-alpha (TNF-alpha) inhibitors with a varying degrees of effect. We performed a systematic review of papers retrieved from two databases (PubMed and Web of Science) using the follow-ing keywords: hidradenitis suppurativa, acne inversa, infliximab, etanercept, and adalimumab. A total of 34 publications were retrieved, describing treatment of 105 patients. Most cases report treatment with infliximab (52/105). A positive treatment outcome was reported in 90/105 cases, with only 7/105 non-responders and 8/105 patients experiencing side-effects. The side-effects were comparable to those seen in other TNF-alpha inhibitor studies. In the majority of cases the treatment was effective when given as a suppressive therapy, but 15/105 cases were described with long-term remission (>or= 3 months) after the end of therapy. In most publications follow-up was, however, insufficient to allow a systematic exploration of this. TNF-alpha inhibitors seem to be effective in the treatment of HS. However, several questions remain to be answered through specific studies. This review has also identified a need for more standardized reporting of the outcomes as well as randomized controlled trials in this disease.

show abstract